Published in Int J Gen Med on December 15, 2010
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability. Int J Radiat Oncol Biol Phys (2003) 1.62
Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet (2003) 1.47
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin Cancer Res (2005) 1.29
Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv Exp Med Biol (2003) 1.18
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol (2004) 1.15
Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. Anticancer Drugs (2005) 1.09
Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane. J Control Release (2005) 1.01
Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. Int J Nanomedicine (2006) 1.00
Prothrombin time after heparin removal. Application to monitoring simultaneous anticoagulation with heparin and coumarins. Am J Clin Pathol (1979) 0.98
CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clin Lung Cancer (2004) 0.89
Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors. Cancer Invest (2005) 0.87
Unfractionated heparin and other antithrombin mediated anticoagulants. Clin Lab Sci (2004) 0.81
Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol (2006) 2.27
siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev (2009) 1.91
Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol (2005) 1.83
Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther (2005) 1.81
Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol (2012) 1.59
Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther (2005) 1.53
Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther (2008) 1.51
A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther (2009) 1.50
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther (2003) 1.40
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer (2012) 1.36
mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int J Oncol (2007) 1.34
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res (2013) 1.31
A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res (2011) 1.27
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest Endosc (2012) 1.19
Oncolytic viruses for induction of anti-tumor immunity. Curr Pharm Biotechnol (2012) 1.18
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Res (2003) 1.16
Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin. J Med Chem (2003) 1.15
Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol Ther (2011) 1.15
Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac Oncol (2008) 1.14
Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac Oncol (2008) 1.13
Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol (2006) 1.12
RNA interference and cancer therapy. Pharm Res (2011) 1.11
Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther (2013) 1.08
In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases. Cancer Chemother Pharmacol (2006) 1.05
Substrate specificity of lysophosphatidic acid acyltransferase beta -- evidence from membrane and whole cell assays. J Lipid Res (2005) 1.04
TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up. Ann Surg Oncol (2005) 1.02
Case report of an acquired factor XIII inhibitor: diagnosis and management. Proc (Bayl Univ Med Cent) (2006) 1.02
Inhibition of lysophosphatidic acid acyltransferase beta disrupts proliferative and survival signals in normal cells and induces apoptosis of tumor cells. Mol Cancer Ther (2003) 1.00
Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. Int J Nanomedicine (2006) 1.00
A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res (2004) 1.00
Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin Cancer Res (2011) 0.99
Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol (2008) 0.97
Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J Thorac Oncol (2009) 0.95
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients. J Pharmacol Exp Ther (2012) 0.94
Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex. Hum Gene Ther (2011) 0.93
p53 therapy in a patient with Li-Fraumeni syndrome. Mol Cancer Ther (2007) 0.91
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene (2005) 0.91
Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist (2011) 0.90
Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy. Cancer Invest (2006) 0.90
Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy. J Gene Med (2010) 0.90
Phospholipase C delta-4 overexpression upregulates ErbB1/2 expression, Erk signaling pathway, and proliferation in MCF-7 cells. Mol Cancer (2004) 0.89
Lysophosphatidic acid acyltransferase-beta: a novel target for induction of tumour cell apoptosis. Expert Opin Ther Targets (2003) 0.88
PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platform. PLoS One (2012) 0.88
Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders. Transplantation (2002) 0.88
Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther (2006) 0.88
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. Gastrointest Endosc (2012) 0.87
Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors. Cancer Invest (2005) 0.87
Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas. Clin Cancer Res (2005) 0.86
Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG™) in advanced cancer of the liver. Oncology (2014) 0.86
Lymphoma and immunosuppression: a report of a case associated with efalizumab therapy. Clin Lymphoma Myeloma Leuk (2010) 0.86
In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein. DNA Cell Biol (2011) 0.85
Fondaparinux-associated heparin-induced thrombocytopenia. Proc (Bayl Univ Med Cent) (2012) 0.85
RNA interference and personalized cancer therapy. Discov Med (2013) 0.83
Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib. Clin Cancer Res (2006) 0.81
Synthesis, SAR, and antitumor properties of diamino-C,N-diarylpyrimidine positional isomers: inhibitors of lysophosphatidic acid acyltransferase-beta. Bioorg Med Chem Lett (2004) 0.81
Biopsy-proven mantle cell lymphoma in brain parenchyma. Proc (Bayl Univ Med Cent) (2011) 0.80
Novel bis-platinum complexes endowed with an improved pharmacological profile. Mol Pharm (2010) 0.80
A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. Cancer Chemother Pharmacol (2008) 0.80
Preclinical assessment of wt GNE gene plasmid for management of hereditary inclusion body myopathy 2 (HIBM2). Gene Regul Syst Bio (2008) 0.79
Effect of lysophosphatidic acid acyltransferase-beta inhibition in acute leukemia. Leuk Res (2006) 0.79
Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res (2005) 0.79
Systemic therapeutic gene delivery for cancer: crafting Paris' arrow. Curr Gene Ther (2009) 0.79
Reversible masking using low-molecular-weight neutral lipids to achieve optimal-targeted delivery. J Drug Deliv (2012) 0.78
Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma. Leuk Lymphoma (2011) 0.78
Copper deficiency (hypocupremia) and pancytopenia late after gastric bypass surgery. Proc (Bayl Univ Med Cent) (2013) 0.78
Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease. ISRN Oncol (2012) 0.77
Conservative surgery and radiation therapy for macroscopically multiple ipsilateral invasive breast cancers. Am J Surg (2002) 0.77
Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation. Semin Radiat Oncol (2002) 0.76
Safety and in vivo expression of a GNE-transgene: a novel treatment approach for hereditary inclusion body myopathy-2. Gene Regul Syst Bio (2009) 0.76
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck. Invest New Drugs (2014) 0.76
Radiopharmaceutical reimbursement rates. JAMA (2008) 0.75
Letter to the editor: Does dicer expression affect shRNA processing? Gene Regul Syst Bio (2009) 0.75
Continuity of research outcomes: the correlation of bench toxicity mechanisms to clinical outcomes--are they dependable? Am J Kidney Dis (2002) 0.75
Optimization of Non-Viral Gene Therapeutics Using Bilamellar Invaginated Vesicles. J Genet Syndr Gene Ther (2011) 0.75
T-cell prolymphocytic leukemia. Proc (Bayl Univ Med Cent) (2013) 0.75
Putting a cost on extra days given by drugs. Pharos Alpha Omega Alpha Honor Med Soc (2008) 0.75
Bifunctional short hairpin RNA (bi-shRNA): design and pathway to clinical application. Methods Mol Biol (2013) 0.75
Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy. J Pediatr Hematol Oncol (2017) 0.75
Diamino-C,N-diarylpyridine positional isomers as inhibitors of lysophosphatidic acid acyltransferase-beta. Bioorg Med Chem Lett (2005) 0.75
Embryonal rhabdomyosarcoma in a young Maine coon cat. J Am Anim Hosp Assoc (2009) 0.75
Enhanced oncolytic potency of replicative adenovirus expressing p53. Drug Resist Updat (2003) 0.75
Phase I trial of an all-oral combination chemotherapy regimen: topotecan and capecitabine in solid tumor patients. J Oncol Manag (2005) 0.75
Individualised cancer therapeutics: dream or reality? Therapeutics construction. Expert Opin Biol Ther (2005) 0.75
Feasibility of amifostine administration in conjunction with high-dose rate brachytherapy. Semin Oncol (2003) 0.75